PE
MRNA icon

Point72 Europe’s Moderna MRNA Stock Holding History

Point72 Europe’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$314K Buy
+12,172
New +$340K 0.02% 163

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Europe's MRNA Position: Q3 2025 in Review

Point72 Europe opened a new position in Moderna (MRNA) in Q3 2025: 12,172 shares worth $314K. The stake represents 0.02% of the portfolio and ranks #163 among its holdings.

643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Point72 Europe held 12,172 shares of Moderna worth $314K as of Q3 2025.
  • Moderna was a new Point72 Europe position in Q3 2025.
  • Moderna made up 0.02% of Point72 Europe's portfolio in Q3 2025, its #163 holding.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.